oxcarbazepine · Supernus Pharms · NDA 202810
Oxtellar Xr
Earliest generic entry, as listed · earliest of 3 marketed strengths
13 Apr 2027
Blocked by patent: US 10220042, US 11166960, US 11896599, US 7722898, US 7910131, US 8617600, US 8821930, US 9119791, US 9351975, US 9370525, US 9855278.
Listed patents · 11 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10220042 | use U-2501 · sets the listed date | 13 Apr 2027 |
| US 11166960 | drug product · sets the listed date | 13 Apr 2027 |
| US 11896599 | drug product · sets the listed date | 13 Apr 2027 |
| US 7722898 | drug product · sets the listed date | 13 Apr 2027 |
| US 7910131 | use U-2041 · sets the listed date | 13 Apr 2027 |
| US 8617600 | drug product · sets the listed date | 13 Apr 2027 |
| US 8821930 | drug product · sets the listed date | 13 Apr 2027 |
| US 9119791 | use U-2041 · sets the listed date | 13 Apr 2027 |
| US 9351975 | drug product · sets the listed date | 13 Apr 2027 |
| US 9370525 | drug product · sets the listed date | 13 Apr 2027 |
| US 9855278 | drug product · sets the listed date | 13 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent · 202810-00313 Apr 2027
- 24 Oct 2026Enters 12-month window basis: patent · 202810-00213 Apr 2027
- 24 Oct 2026Enters 12-month window basis: patent · 202810-00113 Apr 2027
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202810 · 001 · RLD | tablet, extended release, oral | 150MG | 13 Apr 2027 |
| 202810 · 002 · RLD | tablet, extended release, oral | 300MG | 13 Apr 2027 |
| 202810 · 003 · RLD | tablet, extended release, oral | 600MG | 13 Apr 2027 |